Goldman Sachs analysts removed Novo Nordisk (NVO) from its European Conviction List as part of its monthly update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Hims & Hers Health (HIMS) Is About to Report Q2 Earnings. Here’s What to Expect
- Trump posts letters calling on drug company CEOs to lower prices
- Novo Nordisk downgraded to Hold from Buy at HSBC
- Is Novo Nordisk Stock a Falling Knife? Here’s What This Top Investor Thinks
- Novo Nordisk price target lowered to DKK 500 from DKK 650 at JPMorgan